| 12.99 -0.36 (-2.7%) | 01-30 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 17.55 |
1-year : | 19.38 |
| Resists | First : | 15.02 |
Second : | 16.6 |
| Pivot price | 14.71 |
|||
| Supports | First : | 12.47 |
Second : | 10.38 |
| MAs | MA(5) : | 13.81 |
MA(20) : | 14.43 |
| MA(100) : | 12.6  |
MA(250) : | 0 | |
| MACD | MACD : | 0 |
Signal : | 0.4 |
| %K %D | K(14,3) : | 7.1 |
D(3) : | 20.4 |
| RSI | RSI(14): 39.3 |
|||
| 52-week | High : | 19.57 | Low : | 4.88 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ AARD ] has closed below the lower bollinger band by 1.1%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ AARD ] is to continue within current trading range. Bollinger Bands are 27.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 13.62 - 13.69 | 13.69 - 13.76 |
| Low: | 12.26 - 12.36 | 12.36 - 12.44 |
| Close: | 12.84 - 12.99 | 12.99 - 13.12 |
Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Its lead product candidate is the ARD-101, an oral gut-restricted small-molecule agonist of certain targeting bitter taste receptors expressed in the gut lumen that is in Phase III clinical trial for hyperphagia associated with Prader-Willi Syndrome, as well as in Phase II clinical trial for hyperphagia associated with acquired hypothalamic obesity resultant from treatment of craniopharyngioma, including surgery or radiation. It also developing ARD-201, which is in Phase I clinical trial for the treatment of obesity. The company was incorporated in 2017 and is based in San Diego, California.
Fri, 16 Jan 2026
Aardvark Therapeutics, Inc. (NASDAQ:AARD) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Fri, 12 Dec 2025
Sun Nelson, CFO, buys Aardvark Therapeutics shares worth $43,200 - Investing.com
Tue, 16 Sep 2025
Aardvark therapeutics CEO Lee Tien-Li buys $96,623 in shares - Investing.com
Fri, 12 Sep 2025
Aardvark therapeutics CEO Lee Tien-Li buys $160k in AARD - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 22 (M) |
| Shares Float | 11 (M) |
| Held by Insiders | 14.5 (%) |
| Held by Institutions | 53.2 (%) |
| Shares Short | 1,670 (K) |
| Shares Short P.Month | 1,300 (K) |
| EPS | -2.53 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 5.63 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -30.9 % |
| Return on Equity (ttm) | -48.1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.46 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -45 (M) |
| Levered Free Cash Flow | -25 (M) |
| PE Ratio | -5.14 |
| PEG Ratio | 0 |
| Price to Book value | 2.3 |
| Price to Sales | 0 |
| Price to Cash Flow | -6.28 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|